control subjects. S-IRPH was above the 95 % confidence limit of the controls in about 70 % of the patients with active systemic lupus erythematosus, rheumatoid arthritis, scleroderma, Reiter In the patients with SLE and RA about half of the S-IRPH values in subgroup 1 (4 out of 10 with SLE and 2 out of 4 with RA) and 80-90% in subgroup 2 (5 out of 6 with SLE and 7 out of 8 with RA) were above the normal upper limit 1-58 mg/I, defined as the mean + 2 SD of the controls (Fig. 1) , whereas none of the 8 values in cases of inactive SLE and RA was above the limit. All 3 patients with very active SCL and all with very active Reiter's syndrome, polyarteritis nodosa, or polymyositis likewise had S-IRPH values exceeding the normal upper limit, whereas the patient with Reiter's syndrome belonging to subgroup 1 had a value below the limit. One of the 2 values for inactive SCL was elevated. An extremely high value was found in the 1 active case of Sj6gren's syndrome, which had an ESR of 41 on the day of the study, although much higher values were frequently recorded. The patients with AS differed clearly from the others in that only 1 out of 6 S-IRPH values in subgroup 1 and neither of the 2 in subgroup 2 exceeded the normal upper limit (Fig. 1) , even though the mean ESR values for AS cases in subgroups 1 and 2 were essentially identical with those in the corresponding subgroups of the whole patient series. There was a highly significant correlation between S-IRPH and ESR in SLE (r =0 * 687, P <0 * 001), a weak correlation in RA (r=0 559, P<0 05) and a significant correlation in the whole patient series excluding AS (r=0 400, P<0 01), whereas no correlation was found in AS (r=0 230).
Discussion
The results indicate that S-IRPH is above the normal upper limit in about 70% of all patients with the active diseases studied here, excluding AS, but is below this limit in about 90% of those with an inactive disease. High values were found in about half of the cases in subgroup 1 (ESR 21-50) and in about 90 % in subgroup 2 (ESR > 50). These findings agree with those reported previously in patients having active systemic connective tissue diseases with skin manifestations (see above), in that out of these 7 patients, all of whom had an ESR of 21-50, 4 had an elevated S-IRPH. These data thus provide a further parameter pointing to distinct changes in collagen metabolism in connective tissue diseases.
High S-IRPH concentrations have previously been reported in patients with increased prolyl hydroxylase activity in the liver, including cancer with liver metastases,31 27 and in a few patients having malignant diseases without liver involvement, whereas essentially all the patients with dermatological diseases having an increased prolyl hydroxylase activity in the skin lesions had normal S-IRPH concentrations.32 In liver diseases a significant correlation was found between prolyl hydroxylase activity in the hepatic biopsy specimens and S-IRPH concentration.37 It thus seems that an elevated prolyl hydroxylase activity in the liver alone can be 
